Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer
Authors:
Open Access
- 28 June 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (28) , 25368-25380
Abstract
Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancerKeywords
This publication has 22 references indexed in Scilit:
- Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human gliomaJournal of Translational Medicine, 2011
- Remote Communication through Solute Carriers and ATP Binding Cassette Drug Transporter Pathways: An Update on the Remote Sensing and Signaling HypothesisMolecular Pharmacology, 2011
- Clinical Validation of Colorectal Cancer Biomarkers Identified from Bioinformatics Analysis of Public Expression DataClinical Cancer Research, 2011
- Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer ConferenceJapanese Journal of Clinical Oncology, 2010
- International Trends in Colorectal Cancer Incidence RatesCancer Epidemiology, Biomarkers & Prevention, 2009
- KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancerMolecular Cancer Therapeutics, 2009
- Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of RadiologyGastroenterology, 2008
- SOX10 Maintains Multipotency and Inhibits Neuronal Differentiation of Neural Crest Stem CellsNeuron, 2003
- Genomic Imprinting: Implications for Human DiseaseThe American Journal of Pathology, 1999
- Report of the committee on chromosome and gene loss in human neoplasiaCytogenetic and Genome Research, 1991